Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Pharming receives complete response letter from FDA for Ruconest

Sep. 21, 2018

Efgartigimod phase II data in ITP support progression to phase III development

Sep. 17, 2018

Arrowhead Pharmaceuticals patents RNAi for thromboembolic disorders

Sep. 14, 2018

Verseon initiates phase I trial with anticoagulant VE-1902

Sep. 13, 2018

European Commission approves Veyvondi for adults with von Willebrand disease

Sep. 12, 2018

Positive results reported across multiple endpoints in ZENITH-1 trial of oral BCX-7353

Sep. 5, 2018

SRC-3 shushes stem cells

Sep. 5, 2018

European Commission approves Cablivi for acquired thrombotic thrombocytopenic purpura

Sep. 3, 2018

FDA approves Jivi for hemophilia A

Aug. 31, 2018

Sangamo reports positive preliminary data from Alta study of gene therapy for hemophilia A

Aug. 9, 2018

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...